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1. Introduction 
1.1 Endotoxins  
Endotoxins are fragments of the outer membrane of Gram negative bacteria released 
mostly during the cellular lysis (1). 
Lipopolysaccharides (LPS), amphiphilic macromolecules of 10‑20 kDa molecular mass (2), 
are the main component of endotoxins. 
Endotoxins are considered pyrogenic substances, because LPSs can exert toxic effects on 
human including fever, as well as inflammation, disseminated intravascular coagulation 
(DIC), systemic inflammatory response (SIRS) and even at shock and death. 
Although LPS and endotoxin are often used interchangeably in literature, the term 
lipopolysaccharide identifies the pure chemical substance without all the other 
components of the membrane characterizing endotoxins (1). 
Since there are approximately 3.5 . 10 6 LPS molecules per cell (3), Lipopolysaccharides 
occupy about three-quarters of the total Gram negative bacterial surface (~ 4.9 m2) and 
they are involved in the organization and stability of the outer membrane. 
In non-capsulated strains, Lipopolysaccharides are exposed on the cell surface in contact 
with the external environment (Fig. 1). 
Therefore, they play an important role in bacteria’s adhesion to certain tissues (especially 
epithelial tissues) and in establishing a barrier permeable only to hydrophilic low 
molecular weight molecules, preventing penetration of many antimicrobial agents (4). 
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Figure 1 - Membrane structure of Gram-negative bacteria 
 
Structurally, LPS is made up of two moieties connected to each other (from the inside to 
the outside of the bacterial cell) (Fig. 2): 
1) The hydrophobic lipid section, referred to as Lipid A, anchored to the membrane 
through hydrophobic and electrostatic interactions (5), is responsible for most of the 
toxic biological activities of bacterial endotoxins (2). 
2) The hydrophilic heteropolysaccharide section, responsible for the antigenicity of 
bacterial endotoxin, and is constituted by: 
 The R polysaccharide or core, attached to the lipid A; 
 The O polysaccharide side chain or somatic antigen O, attached to the outer core 
of the R polysaccharide. 
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Figure 2 - Molecular structure of Lypopolisaccharide 
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The Lipid A is made up of an amino disaccharide, the -(1,6)- glucosaminyl-- 
glucosamine (1), constituted by two units of glucosamine (2-amino-2-deoxy-D-gluco-
pyranose) linked with a phosphoryl group (1 and 4’ position) and fatty acid chains. 
The fatty acids are responsible of the hydrophobic nature of the molecule and are 
referred to as (5): 
- primary, if they are in the R configuration, 3-hydroxylated, saturated and directly 
linked to sugar residues via ester (positions 3 and 3’) or amide (positions 2 and 2’) 
linkages; 
- secondary, if they are in the S configuration, saturated and linked to the primary 
fatty acids in position 3 by an ester bond. 
Primary fatty acids are typical of lipid A, and, are consequently considered markers of 
Gram negative bacteria. 
Although lipid A is the most conserved part of endotoxin within the species, its fine 
structure may vary, in terms of the type of hexosamine present, the degree of 
phosphorylation, the presence of phosphate substituents and the nature, chain length, 
number and location of acyl groups (3). 
 
The R polysaccharide or core is attached to the 6’-position of glucosamine with an 
unstable β-(2 → 6) polysaccharidic bond. 
The R polysaccharide consists in an inner portion and outer one.  
The inner portion is a short oligosaccharide chain composed by two unusual sugars (Fig. 
3),  i.e. the 3‑deoxy-α-D-manno-octulosonic acid (KDO) linked with heptulose (usually L or 
D-glycero-α-D-manno-heptopyranose); these sugars are typically phosphorylated or 
modified with phosphate-containing groups (e.g., pyrophosphate or 
2‑aminoethylphosphate), which give the molecule negative charge to in solutions with a 
pH 2 (6) and they reduce the permeability and increase the stability of the cell membrane 
by electrostatic interactions with external divalent cations (Ca2+, Mg2+) (5). 
In the inner portion of the core there are few differences from one bacterial strain to 
another (1). 
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Figure 3 - Chemical structure of the unusual sugars of antigen R 
The outer portion is structurally more diverse than the inner one, as it contains more 
common hexoses, including glucose, galactose, and N-acetylglucosamine. 
 
The O polysaccharide side chain or somatic antigen O is constituted by oligosaccharides 
composed by two-six sugars and repeated from 20 to 40 times. 
The structure of the repeating units (nature, ring form, sequence, substitution, and type 
of linkage of the monosaccharides residues) differs from strain to strain within a serotype 
(3), making the O-antigen the primary structural constituent of lipopolysaccharide that 
differentiates Gram-negative bacteria. 
Moreover the length of the polysaccharide chain allows the Gram-negative bacteria to be 
divided into two classes: 
- SMOOTH, if the O-chain is long, conferring an uniform appearance to the LPS; 
- ROUGH, if the O-chain is short or absent, conferring a wrinkled appearance to the 
LPS. 
The presence of a long O-chain is important, since it allows the host immune system to be 
evaded: the immune reaction of antibodies and complement takes place at the tips of the 
chain, which is too distant from the bacterial membrane to make the lysis of the cell occur 
(4).  
For this reason the rough strains lose their virulence. 
 
Because of the LPS’s chemical structure, endotoxins have the following physical 
characteristics: 
- As opposed to protein exotoxins, endotoxins are highly heat-stable, so that boiling 
for 30 minutes does not destabilize them; endotoxins are not destroyed under 
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regular sterilizing conditions and are resistant to oxidizing agents such as 
peroxides and hypochlorite. 
- In aqueous solutions, endotoxins can exist in various supra-molecular aggregates 
for the establishment of different types of non-covalent bonds: non-polar 
interactions between lipid chains, hydrogen bond between water and the hydroxyl 
groups of the sugars and ionic interaction among phosphate groups and divalent 
cations present in aqueous solutions; aggregates’ stability depends on the 
solution’s characteristics (pH, ions, surfactants, etc). 
The aggregates can have a variety of shapes (lamella, cubic and hexagonal) with a 
molecular mass range of 1000-4000 kDa and diameters up to 0.1 mm (2). 
Therefore they can easily pass through a 0.2 μm sterilizing-grade membrane filter 
where size exclusion is the sole retention mechanism (18). 
Due to the high variability of their molecular weight and the particular chemical-physical 
properties of LPS, it can be often difficult to remove endotoxins. Existing removal 
methods include anion exchange chromatography, ultrafiltration, distillation, reverse 
osmosis and the inactivating techniques are acid-base hydrolysis  of LPS, oxidation, 
sodium hydroxide and heat depyrogenation (7). 
Generally, most endotoxins remain associated with the cell until cellular lysis occurs, but 
Gram-negative bacteria can also release endotoxins also during growth and division. 
Cellular lysis can be induced by various mechanisms that compromise cellular integrity, 
such as those of viral, osmotic, mechanical and enzymatic (complement system, 
lysozyme, digestion by macrophages or auto-lysis) origins (2) or those that are antibiotic-
induced (8). 
Humans may be exposed to endotoxins by injection, ingestion, inhalation or muco-
cutaneous contact (9) from exogenous sources and by bacterial translocation of 
endogenous nonpathogenic Gram-negative bacteria of bacterial flora from the gut when 
breakdown in gut mucosal integrity and/or impairment of the liver occur. 
The response to endotoxins varies based on the dosage, site or route of exposure and 
speed with which they are released into the blood system (endotoxemia). 
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In contrast to exotoxins, endotoxins do not elicit their toxic effects selectively by killing 
host cells or by inhibiting cellular functions, rather, their LPSs activate various 
endogenous interlinked pathways and cascade mechanisms (Fig. 4) (10). 
 
Figure 4 - Endogenous interlinked pathway activated in the host response to endotoxin 
 
Therefore, endotoxins have been implicated as the aetiological agent in a variety of 
pathologies, including the most serious sepsis and systemic inflammatory response (SIRS), 
i.e. overwhelming inflammatory host responses induced once endotoxins are present in 
bloodstreams; they can manifest as fever, vascular leakage, myocardial depression and 
disseminated intravascular coagulation (DIC).  The difference between sepsis and SIRS is 
the presence of a detectable infection in the first one (e.g., meningococcemia); both can 
progress to shock, a catastrophic syndrome characterized by refractory hypotension, 
multiple organ failure and death (8). 
 
The most widely studied and probably the most significant cellular mechanism involves 
the endotoxin interaction with the immune innate system. In this case the endotoxin 
behaves like pathogen-associated molecular patterns (PAMP), i.e. a molecule associated 
with a specified group of pathogens and recognized by cells of the innate immune 
system through, for example, Toll-like receptors (TLRs) (11). 
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The reaction begins when endotoxins arrive in the bloodstream and create a series of 
complexes with different proteins, leading to gene translation which codify pro-
inflammatory and pyrogenic molecules. 
The molecular steps of the immune reaction are shown in Figure 5:  
 
Figure 5 - Endotoxin molecular interaction mechanism with the innate immune system 
 
 In bloodstream, the LPS-binding protein (LBP), an acute-phase circulating protein 
produced in the liver, recognizes and forms a high-affinity complex with the lipid A 
moiety of LPS, in the form of free molecules, fragments, or still bound to the outer 
membrane of intact bacteria (12). The role of LBP appears to be that of aiding LPS to 
dock at the LPS receptor complex. 
 
 The LPS/LBP dimer creates a ternary complex  with the cluster of differentiation 14 
(CD14), a protein which exists in two forms: a membrane bond form (mCD14), attached 
to the surface of myeloid cells via a glycosylphosphatidylinositol tail, and a soluble 
form (sCD14), circulating in plasma and conveying LPS signaling in endothelial and 
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epithelial cells (lacking of mCD14). CD14 can’t operate as an LPS receptor, lacking of a 
transmembrane domain, thus it simply presents LPS to its receptor (12). 
 
 The LPS binds an extracellular secreted adaptor glycoprotein, the myeloid 
differentiation 2 (MD-2), which in turn associates with the Toll-like receptor-4 (TLR4), 
creating an homodimer signaling receptor. This event triggers signal transduction, 
involving several adapter proteins, and ends with the activation of two transcription 
factors: 
- the Nuclear factor-B (NF - B) which has as target genes those codifying for  
cytokines (IL-1, IL-6, IL-8, IL-10), tumor necrosis factor (TNF-, platelet-activating 
factor and enzymes (iNOS, COX2, elastase and collagenase), the central 
components of the host immune and inflammatory response; 
- the Interferon-stimulated gene factor 3 (ISGF3) which has as target genes the IFN-
stimulated response elements (ISREs) codifying for IFN-  (13, 9). 
Pyrogenic cytokines (IL-1, IL-6), TNF- and IFN- are considered to be the immediate 
triggers of the so called “endotoxic fever”, since they stimulate the hypothalamus 
endothelial cell to produce prostaglandin (PG) E2. The latter are transported by the 
bloodstream to the ventromedial preoptic-anterior hypothalamus (POA, the locus of 
the temperature-regulating center), acting on thermoregulatory neurons.  
LPS’s ability to produce fever allows endotoxins to be classified as pyrogenic 
substances. 
While the risks for human health associated with endotoxins ingestion and transmission 
through a muco-cutaneous route is not well quantified, the adverse effects of intravenous 
injection and inhalation are well known. 
In fact, all the major pharmacopoeias (European Pharmacopoeia, United States 
Pharmacopoeia and Japanese Pharmacopoeia) consider endotoxins from Gram-negative 
bacteria to be “the most common cause of toxic reactions from contamination of 
pharmaceutical products with pyrogens” (14) and they provide specific production 
processes and tests to ensure the absence of endotoxins in parenteral preparations 
intended for administration by injection or infusion into human or animal bodies (15, 16, 
17). 
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The pharmacopoeias set a threshold endotoxin concentration for parenteral drugs (EL) in 
order to ensure that “as long as the endotoxin concentration in the product remains 
below this threshold even the maximal drug dose administered parenterally  by the 
intended route per hour does not contain sufficient endotoxin to cause a toxic reaction” 
(14): 
EL (IU/mL or IU/mg) = K (IU/Kg) / M (mL/Kg or mg/Kg) 
- K: “threshold pyrogenic dose of endotoxin per kilogram of body mass” (14);  it has 
a different value depending on the route of administration (Fig.6): 
 
Figure 6 - Threshold pyrogenic dose of endotoxin per kilogram of body mass (K) 
 expressed in UI/Kg of body mass (18) 
 
- M: “maximum recommended bolus dose of product per kilogram of body mass” 
(14); when the product is to be injected at frequent intervals or infused 
continuously, M “is the maximum total dose administered in a single hour period” 
(14). 
In recent years, inhalation exposure to endotoxins has gained importance in occupational 
studies, especially due to the development of a “greener” and more resource-efficient 
economy (19). 
The European Agency for Safety and Health at Work (EU- OSHA)  rates airborne 
endotoxins among the “top ten emerging biological risks” (11): positive associations 
between endotoxin exposure and respiratory disorders have been reported mostly in 
occupational sectors such as those of primary production and agriculture (animal 
husbandry, the cultivation and harvest of corn, cotton, potatoes, animal feed industry, 
slaughter houses), those that handle organic materials (plant selection and composting, 
industrial water treatment and sludge, manual collection and storage of waste, wood and 
composting) (9) and animal technicians, as well as scientists working with rodents (11). 
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The diseases associated with airborne endotoxins are principally caused by the 
production of elastase by the alveolar macrophages, resulting in the decreased of 
elasticity of the fibers of the parenchyma, to the development of pulmonary emphysema 
and stimulation of mucosal secretions (9). 
Acute exposure to endotoxins at levels above 45 IU/m3/day (11)  may cause fever , chills, 
dry cough, chest tightness , dyspnea, nose and throat irritation, shortness of breath, joint 
pain and flu-like symptoms, all symptoms related to inhalation of organic dust toxic 
syndrome (ODTS) and Sick Building Syndrome (SBS). Chronic exposure to endotoxins, at 
levels as low as 10-28 IU/m3 (11) can cause symptoms similar to chronic bronchitis, 
asthma, chronic obstructive pulmonary disease (COPD) and reduced lung function or 
chronic inflammation (9). 
However, in contrast to these negative effects, numerous studies have described 
seemingly paradoxical protective effects of environmental endotoxin exposure on atopic 
asthma risk, the development of allergy in early childhood, and atopy (20) through an 
effect on the balance of T-helper cells 1 and T-helper cells (11). Furthermore, endotoxins 
have been used in artificial fever therapy, to destroy tumors and to improve, non-
specifically, the immune defenses (2).  
 
1.2  Quality Control of parenteral preparations in the 
pharmaceutical industry 
Good manufacturing practices (GMP) are defined by Commission Directive 2003/94/EC as 
“the part of quality assurance which ensures that products are consistently produced and 
controlled in accordance with the quality standards appropriate to their intended use” 
(21). 
The EU’s GMP defines Quality Control as “the part of Good Manufacturing Practice which 
is concerned with sampling, specifications and testing, and with the organization, 
documentation and release procedures which ensure that the necessary and relevant 
tests are actually  carried out and that materials are not released for use, nor products 
released for sale or supply, until their quality has been judged to be satisfactory” (22). 
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GMP ensure quality control by sampling and testing the starting materials, packaging 
materials, intermediate, bulk, and finished products, and, where appropriate, by  
monitoring environmental conditions (22). 
In particular, the quality control of parenteral preparations is handled with special 
attention, since these pharmaceutical forms come into direct contact with the human 
bloodstream. 
European pharmacopoeia (EP) defines parenteral preparations as “sterile preparations 
intended for administration by injection, infusion or implantation into the human or 
animal body” ( 17) and sterility as “the absence of living micro-organisms” (23). 
EP specifies that “parenteral preparations are prepared using materials and methods 
designed to ensure sterility and to avoid the introduction of contaminants and the growth 
of micro-organisms”( 17). Therefore, the EP states: “It is expected that the principles of 
good manufacturing practices (as described in, for example, the European Community 
Guide to GMP) will have been observed in the design of the process (23)”. 
The manufacture of sterile medicines is discussed in Annex 1 of EU GMP and it is based on 
the fact that these products shall be subjected to “special requirements in order to 
minimize risks of microbiological contamination, and of particulate and pyrogen 
contamination” (24). 
This can be guaranteed by the application of a suitably validated production process and 
verification through quality control tests (23). 
First of all, EU GMP provisions for the manufacture of sterile products in clean area, i.e. 
“an area with defined environmental control of particulate and microbial contamination, 
constructed and used in such a way as to reduce the introduction, generation and 
retention of contaminants within the area” (25). Moreover, each manufacturing 
operation “requires an appropriate environmental cleanliness level in the operational 
state”, therefore it “should be carried out in separate areas within the clean area”(24). 
For the manufacture of sterile medicinal products 4 grades are provisioned by GMP (24):  
- Grade A  for high risk operations making aseptic connections, i.e. filling zone, stopper 
bowls, open ampoules and vials. Normally a laminar air flow work station is present to 
assure aseptic conditions. 
- Grade B as a background environment for the grade A zone for aseptic preparation and 
filling. 
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- Grade C and D for carrying out less critical stages in the manufacturing processes, such 
as preparing non sterile solutions and washing vials. 
In order to guarantee the quality of the parenteral products, EU GMP provisions for clean 
areas in-process environmental monitoring of airborne particle concentration and 
microbial contamination. Monitoring shall be carried out “in operation” state, i.e. “the 
condition where the installation is functioning in the defined operating mode with the 
specified number of personnel working” (24), and in specific sampling locations, found 
through a formal risk analysis study based on EN/ISO 14644 standard. 
Airborne particles are quantified with portable particle counters while, microbial 
contamination is monitored with settle plates, volumetric air and surface sampling (i.e. 
swabs and contact plates) (24). 
The limits chosen by EU GMP for these two types of environmental monitoring are 
reported in the following Tables (1 and 2):   
 
Table 1 - EU GMP Annex 1 maximum permitted number of particles per m3 equal or greater than 
the tabulated size and the corresponding ISO 14644 contamination classes (24, 26) 
 
 
Table 2 - EU GMP Annex 1 recommended limits for microbial contamination (24) 
 
Particles size 0.5 m 5.0 m 0.5 m 5.0 m
3520 20 3520 20
(ISO Class 4.8) (ISO Class 4.8) (ISO Class 4.8) (ISO Class 4.8)
3520 29 352000 2900
(ISO Class 5) (ISO Class 5) (ISO Class 7) (ISO Class 7)
352000 2900 3520000 29000
(ISO Class 7) (ISO Class 7) (ISO Class 8) (ISO Class 8)
3520000 29000 Not defined Not defined
(ISO Class 8) (ISO Class 8) (ISO Class not defined) (ISO Class not defined)
At rest In operation
Grade A
Grade B
Grade C
Grade D
Contact plates
Ø 55 mm
(CFU/plates)
Grade A < 1 < 1 < 1 < 1
Grade B 10 5 5 5
Grade C 100 50 25 -
Grade D 200 100 50 -
Air sample 
(CFU/m
3
)
Settled plates  
sample Ø 90 mm 
(CFU/4h)
Glove print 
5fingers 
(CFU/glove)
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Although the EU’s GMP consider pyrogens among the primary risks for the quality of 
sterile products and although the presence of airborne endotoxins is known to exist in 
most occupational settings (11), nothing has been specified in Annex 1 or in other literary 
sources about the in-process environmental monitoring of airborne endotoxins in clean 
areas. 
Sources of ubiquitous Gram-negative bacteria are actually known to exist in clean rooms, 
such as settled dust, washed or rinsed plastic devices or water used as a solvent or in 
processing. Intuitively speaking, endotoxins can become airborne during occupational 
practices that include the manipulation of these sources, which cause bacteria cell 
rupture by dehydration and mechanical impact. 
 
In order to guarantee the sterility of parenteral preparations the preferred method is 
overkill final steam sterilization (23), which involves the use of saturated steam under 
pressure in an autoclave at a minimum of 121 °C for 15 min on the product in  its final 
container. 
The aim sterilization process is to obtain a “sterility assurance level” (SAL) of 10−6 or 
better, i.e. “a probability of not more than one viable micro-organism in 1 × 106 sterilized 
items of the final product” (23), given that “the achievement of sterility within any one 
item in a population of items submitted to a sterilization process cannot be guaranteed 
nor can it be demonstrated” (23). 
Other terminal sterilization procedures include: dry heat (at a minimum of 160 °C for at 
least 2 h), ionizing radiation in the form of gamma radiation from a suitable radio-isotopic 
source (at a absorbed dose of 25 kGy) and gas (ethylene oxide). If terminal sterilization is 
not possible, an aseptic processing of a pre-sterilized product can be performed by 
filtration through a bacteria retaining filter with a nominal pore size of 0.22 μm as close as 
possible to the filling point (23). 
The removal of pyrogens provisions a depyrogenation with dry heat in an hot-air oven at 
temperature capable of reducing the endotoxin content by at least 3 log, e.g. at 250 º C 
for more than 30 minutes (18) or at 180 ° C for more than 3 hours (27). This is to be 
carried put exclusively  on primary open packaging materials (i.e vials). 
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The microbiological quality control assays required for parenteral preparations are the 
sterility test and the research of bacterial endotoxins or, where justified, the pyrogens 
test (24, 14). 
The sterility test “only indicates that no contaminating micro-organism has been found in 
the sample examined” (16). This is carried out in asepsis after sterilization of the product 
by direct inoculation of the latter on suitable culture media (fluid thioglycollate medium 
principally for anaerobic bacteria and soya-bean casein digest medium for both fungi and 
aerobic bacteria) or by using the membrane filtration technique, which provisions for the 
incubation in the culture medium of the filters (nominal pore size not greater than 0.45 
µm) on which the product to be tested was previously transferred (16). 
 
For parenteral preparations administered by injection or infusion, the test for bacterial 
endotoxins (BET) or, where justified, the test for pyrogens, is carried out on starting 
materials, Water for Injection (WFI) and finished products ( 17). 
For EP: “Endotoxins from gram-negative bacteria are the most common cause of toxic 
reactions from contamination of pharmaceutical products with pyrogens; their pyrogenic 
activity is much higher than that of most other pyrogenic substances” and “the absence 
of bacterial endotoxins in a product implies the absence of pyrogenic components, 
provided the presence of non-endotoxin pyrogenic substances can be ruled out” (14). 
The test for pyrogens, developed in the 1920s (2), “consists of measuring the rise in body 
temperature evoked in rabbits by intravenous injection of a sterile solution of the 
substance to be examined” (28). 
This in vivo test is elaborate, expensive, time consuming, not quantitative, and 
questioned by directive 2010/63 for the protection of animals used for scientific 
purposes. This explains why  the Lymulus amebocyte lysate (LAL) test, developed by 
Leving and Bang in 1964 and recognized by the Food and Drug Administration (FDA) in 
1983 as a valid method for the detection or quantification of endotoxins (29), is currently 
preferred by pharmacopoeias for its simplicity, sensitivity and reproducibility. 
LAL, the lyophilized lysate of the horseshoe crab (Limulus polyphemus) amoebocytes (i.e. 
emolymph cells), leads to the activation of a proteolytic clotting cascade in the presence 
of endotoxins. This enzymatic reaction (Fig. 7) provides for the transformation of 
proenzyme into an active enzyme, up to the development of a clot:  
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Figure 7 - Amebocyte proteolytic clotting cascade 
               
The EP identifies three techniques for the LAL test (18): 
a) gel-clot technique, which detects endotoxins, based on the visual observation of a 
gel formation after the clotting of the lysate in the presence of endotoxins. This 
test can be qualitative or quantitative if, respectively, one or more dilutions of the 
sample are tested. 
b) turbidimetric technique, a photometric assay that measures the increase in 
turbidity after the cleavage of an endogenous substrate.  
c) chromogenic technique, a photometric assay that measures the increase of color 
due to the release of para-nitroaniline, after the cleavage of a synthetic peptide-
chromogen complex (5-pep + p-nitroaniline) by coagulase. 
Endotoxins
Factor C
Activated 
Factor C
Factor B
Activated 
Factor B
Procoagulase Coagulase
Coagulogen Coagulin
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Figure 8 - Photometric techniques: relationship between reaction times  
and OD at specific endotoxin concentrations (30) 
 
Depending on the principle employed, the photometric techniques can be classified as: 
- end-point test, based on the quantitative relationship between the endotoxin 
concentration and the absorbance at the end of a specific incubation period.  
 
Figure 9 - End-point test principle: relationship between reaction times 
and endotoxin concentrations (30) 
 
- kinetic test, which measures the time (on-set time) needed for the reaction 
mixture to reach a predetermined absorbance or optical density (OD). 
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Figure 10 - Kinetic test principle: relationship between reaction times 
and endotoxin concentrations (30) 
 
The amount of endotoxin is no longer expressed in units of weight, since the biological 
activity of endotoxins varies greatly between Gram-negative bacterial species and 
between different strains of the same species, primarily for the differences in endotoxin 
molecular weight. Therefore, endotoxins are tested for their activity, correlated with 
pyrogenicity (i. e. the ability of the endotoxin to induce fever) or LAL reactivity (31). 
For this reason, the results of LAL test are expressed in International Units (IU) or in 
exactly equivalent Endotoxin units (E.U.), defined by the EP as “the specific activity of a 
defined mass of the World Health Organization (WHO) International Standard for 
endotoxin” (14). 
The EP considers the WHO International Standard for endotoxin to be the Reference 
Standard Endotoxin (RSE) against which the Control standard endotoxin (CSE) is 
calibrated, i.e.  the endotoxin standard for Biological Reference preparation (BRP) (31). 
RSE is assigned a potency (or activity), expressed in IU/vial or IU/ng, in order to define 
how many ng’s of theendotoxin used correspond to 1 IU; the CSE, born as an economical 
alternative to the RSE, is calibrated against RSE, specifying the LAL reagent batch used 
(potency of endotoxin varies when determined with different LAL lots). 
The RSE is prepared by extraction, purification and lyophilization of LPSs from Escherichia 
coli O113:H10K (31). The potency of extracted LPS is also significantly influenced by 
physical and solubility characteristics that determine its macromolecular aggregation (10).  
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The use of IU as the unit of measure allows results of different LAL tests performed in 
different labs  to be compared and to trace the endotoxin concentration in the sample 
considering that  its activity is equivalent to that of a stated mass of standard endotoxin, 
even though these two type of endotoxins do not have the same chemical-physical 
characteristics (31). 
 
The LAL assay is very sensitive, ranging from a minimum detectable concentration of  
0.01 - 0.005IU/mL to a maximum of 20 - 50 IU/mL. Therefore, it is crucial to: 
- Apply procedures that limit the risks of contamination. 
- Check the suitability of materials used in the test, since endotoxins may be 
adsorbed onto the surface of tubes or pipettes made from certain plastics or glass 
or plastic materials that can release certain substances, creating interferences 
(14). 
- Respect the optimal conditions required for a valid conduction of the test (pH, 
ionic strength, temperature, and time of incubation): a study conducted by F. 
Rebello Lourenço shows that simultaneous differences in these parameters 
significantly increase the frequency of false-positive responses, mostly the 
variations from the pH optimal value 6.0÷8.0 (32). 
- Confirm the labelled lysate sensitivity with the end-point gel-clot technique or to 
assure the criteria for the standard curve on which the quantitative test has been 
performed: the absolute value of the correlation coefficient, |r|, must be greater 
than or equal to 0.980 for at least 3 replicates of 3 standard endotoxins 
concentration, chose within the interval indicated by the lysate manufacturer (14).  
- Carry out a preliminary test to check the presence of interfering factors (as -
glucans). The test for interfering factors considers that the lysate sensitivity, in the 
presence of the product added with an endotoxin concentration equal to the 
middle concentration of the standard curve (Spiked sample), is at least 0.5 times 
and not more than twice compared to that of lysate on its own (14). 
- Guarantee the removal of interfering factors (14). 
- Proceed with a negative control to verify the absence of endotoxins in the water 
for BET or LAL reagent water (LRW) and in the other reagents (surfactants, buffers 
etc.) (14). 
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- Define the Maximum Valid Dilution (MVD), i.e. “the maximum allowable dilution 
of a sample at which the endotoxin limit can be determined” (18).  
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2. Aim of the thesis 
This thesis originates from the combination of my desire to explore the research themes 
of the pharmaceutical industry and the willingness of Abiogen Pharma S.p.a. to involve 
me in one of Its internal research project.  
The aim of the thesis is to quantify airborne endotoxins in production environments of 
injectable drugs, in order to evaluate the quality of the process and the risk for the 
products manufactured therein. 
This project derives from an awareness about the dangerous effects of injected 
endotoxins on human health and the lack of information on the in-process monitoring of 
airborne endotoxins in production environments of injectable drugs. In fact, although 
airborne endotoxins are widely known to exist in  most occupational settings along with 
sources of Gram-negative bacteria in clean areas, nothing is specified about this topic in 
scientific literature.  
 
In order to begin the experimental portion of my thesis, I received training on 
occupational Health and Safety issues at Abiogen Pharma, in accordance with Legislative 
Decree 81/08 (and subsequent amendments) and on the principles of Good 
Manufacturing Practices (GMP) that affect my experimental aims, in order to work in a 
safe and reliable way. 
 
In order to quantify airborne endotoxins in production environments of injectable drugs, 
we developed a method based on the standard guideline EN 14031:2005 (“Workplace 
atmospheres - Determination of airborne endotoxins"). For this purpose, we conducted a 
validation test which allowed us to define the method’s critical parameters to ensure the 
reproducibility and the reliability of the data collected. 
 
We also decidedto test for the presence of an objectionable past or current Gram-
negative bacteria environmental contamination in production environments of injectable 
drugs, in order to assess any potential correlation with airborne endotoxins. 
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We developed a method to quantify both the airborne Gram-negative bacteria and those 
present on surfaces, respectively using settling and contact plates both containing a 
selective medium for the growth of such bacteria (VRBGA : Violet Red Bile Glucose Agar). 
 
Once the methods were validated, we constructed the pattern of the environmental 
monitoring, identifying the injectable drug production areas where there is a greater 
presence of possible sources of Gram-negative bacteria. Therefore, we selected three 
rooms where water is extensively used: product solutions and material preparation 
rooms (Grade C) and the vial washing area (GradeD). 
We then selected sampling locations, identifying the sites most at risk for bacterial 
contamination. 
Microbiological environmental controls were conducted in operating conditions and three 
times per room, in order to assess the variability of the data and obtain reasonable 
assurance that the results were not due to chance or luck.  
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3. Abiogen Pharma S.p.A. (*) 
Abiogen Pharma S.p.A. is a pharmaceutical company established in Pisa since 1997, 
although its history dates back at the early twentieth century, when it operated under the 
name “Istituto Gentili”, one of most important pharmaceutical operators in Italy.  
Abiogen’s manufacturing, industrial and development activities are conducted in an ultra- 
modern facility located in Ospedaletto (Pisa), with the following departments: oral solids, 
preparations, Asepsis or sterile injectables, semi-solids and oral liquids. 
The company maintained its founder’s name, establishing the “Centro Studi Alfredo Gentili” in 
Pisa. 
 
 
 
 
 
 
 
 
 
 
 
 
(*) cfr with http://www.abiogen.it/it/ 
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4. Training  
Having to enter a working environment, during my permanence in Abiogen Pharma, I 
received two types of training: a 24 hour training on occupational Health and Safety, 
according to Legislative Decree 81/08 (and subsequent amendments) and a training on 
the principles of Good Manufacturing Practices (GMP) that affect my experimental aims. 
  
The first training had the purpose to instruct me on: 
- the professional profiles involved in monitoring and applying practicing Health and 
Safety procedures; 
- the Health and Safety methods that apply to a general working environment; 
- how the above methods can be applied to Abiogen Pharma’s internal protocols. 
The GMP training is based on the following statement included in the Guidelines:  “the 
manufacturer should provide regular training for all the personnel whose duties take 
them into production areas or into control laboratories (including the technical, 
maintenance and cleaning personnel), and for other personnel whose activities could 
affect the quality of the product” (33); that with the purpose of establishing and 
maintaining a satisfactory system of quality warranty and the correct manufacture of 
medicinal products (33).  
 
Since I need to enter both control laboratories and parenteral preparation production 
areas, I have received specific theoretical and practical trainings on these issues for my 
experimental purpose. 
 First of all, I was trained on how to read and follow instructions correctly such as 
standard operative procedures, i.e. literature that describes “the operations to be carried 
out, the precautions to be taken and measures to be applied directly or indirectly related 
to the manufacture of a medicinal product” (25), and then I received behavioral 
instructions as dressing and hygiene and in order to enter the classified (Grade C and D) 
and non-classified quality control laboratories and production areas. 
I was subject to a theoretical and practical verification on the training received “Bacterial 
Endotoxins Test”, gaining the title of technician qualified to perform this assay. 
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Moreover, I have been trained in the use of all the equipment I needed in the 
experimental part and in all the special requirements in order to perform testing 
correctly.  
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5. Development of a method for recovering airborne endotoxins 
5.1 Description 
The only existent European standard which deals with the recovering of airborne 
endotoxins is a guideline issued by the “European Committee for Standardization” with 
the purpose to assess the worker exposure to airborne endotoxins in workplaces (EN 
14031:2005: “Workplace atmospheres - Determination of airborne endotoxins"). 
This standard has been widely criticized for being insufficiently accurate and detailed, 
allowing individual interpretations and, consequently, the development of non-uniform 
methodologies and causing inter-laboratory variability in the results; the lack of 
correlation between the data coming from different studies makes it difficult to establish 
an international exposure limit for the workplace. 
The last occupational exposure limit (OEL) of 90 IU/m3 was proposed in July 2010 by the 
Dutch Expert Committee on Occupational Safety (DECOS), a Committee of the Health 
Council of the Netherlands (34). 
 
Starting from the indications given by EN 14031:2005 (27), our purpose is to conduct a 
validation test which allows us to define critical parameters of the method, thus to ensure 
the reproducibility and the reliability of the data collected. 
 
Generally, measuring airborne endotoxin concentration comprises three crucial steps: air 
sampling, sample transport/storage and sample analysis, i.e. extraction and endotoxin 
assay. 
 For air sampling the standard provides an active sampling, at a flow rate of 2 L/min 
(in order to collect the inhalable aerosol fraction), using a nonpyrogenic glass fiber filter 
(27), while in literature we find also the use of polycarbonate, Teflon, polyvinyl chloride 
(PVC) and cellulose-based media. 
 European standard specifies that the filters for transportation must be placed in a 
sealed container or in a sampling cassette, at ambient temperature and in a dry 
atmosphere or frozen, if the transport period is beyond 24 h. 
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 Under the voice “Storage of samples at the laboratory” EN/UNI 14031 bids: “if 
sample is not extracted within a few days after arrival to the laboratory, the sample shall 
be stored at approximately -20 °C or below”; the standard leaves open to interpretation 
on the time after which the freezing is necessary, the form wherewith the sample should 
be preserved and the maximum time of storage. 
Few studies demonstrate to follow these indications and most of them differs on form of 
storage (filter or extraction solution), temperature (ambient temperature or 4°C), storage 
period (a few hours to several months) and relative humidity of the air in the transport 
enclosure (30). 
 For endotoxin extraction from the matrix the standard provides to use a minimum 
of 5 mL of endotoxinfree water, shake vigorously with a standard shacking apparatus for 
1 hour at room temperature and centrifuge at 1000 x G for 15 minutes with a standard 
table centrifuge; if supernatant cannot be analyzed it should be stored at -20 °C or below 
in tightly sealed tubes for longer time periods (several years). 
Variations in literature are found for extraction parameters: different dilution ration of 
the sample (up to 50) are used and 0.05% aqueous solution of Tween 20 is frequently 
mentioned; moreover, the standard does not give any detail on the speed and type of 
agitation conducted with the shacking apparatus. 
Both EN 14031 and most of the studies for the quantification of endotoxin levels use the 
kinetic chromogenic LAL test and express endotoxin concentration in IU/m3. 
 
Our validation test of the airborne endotoxins method provided (Fig. 8): 
– Verification of the existence of the following properties of the filters used in the 
sampling: 
- Compatibility with test of bacterial endotoxins. 
- Ability to release adsorbed endotoxin in the extraction solution. 
- Absence of irreversible adsorption of bacterial endotoxins after air sampling. 
– Evaluation of filters holding parameters (time and temperature), in order to determine 
sample storage conditions. 
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Figure 11 - Flowchart of airborne endotoxins validation test 
 
All the tests were conducted in triplicate, in order to assess the variability of the data and 
obtain reasonable assurance that the results were not due to chance or luck. 
The LAL reagent employed had a = 0.005 UI/mL. 
We used depyrogenated glass fiber filters (GFF) with nominal pore size of 0.3 μm, since 
the endotoxins are generally considered to be present in the air unaltered, measuring less 
than a typical bacterial cell (1 or 2 μm), or  associated with other biological or non-
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bliological aerosol particles as dust particles or aqueous aerosol, measuring 50 -100 m 
(30). 
The pure, small micro-vesicles of LPS molecules measuring 30 ÷ 50 nm, which may be pass 
through the filter, are considered quite absent in the environment (30); in fact, LPS itself 
can be considered as nonvolatile compounds, since we found that amphipatic molecules 
with much inferior molecular mass both more hydrophobic, as the Tryolein, and more 
hydrophilic, as D-myo-Inositol, have a vapor pressure of 0 mmHg at 25 °C (see Appendix 1 
for more details). 
 
In the first step of the validation test we wanted to assure: 
- the depyrogenation of the filter is effective and the filter did not contain endotoxins; 
- the filter did not release substances that interfere with the test; 
- the extraction conditions did not interfere with BET. 
For this reason GFFs were subjected first to the extraction procedure and then to the test 
for interfering factors as described in European Pharmacopoeia (18); the EP provides the 
preparation of the following four solutions: 
 
Figure 12 - EP experimental pattern for interfering factor test (18) 
 
Where: 
– Solution A = test solution. 
– Solution B = preparation to be examined at the same dilution as solution A, containing 
added endotoxin at a concentration equal to or near the middle of the standard curve 
(Spiked sample). 
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– Solution C = standard endotoxin solution at the concentrations provided by LAL 
reagent manufacturer. 
– Solution D = water for BET (Negative control). 
In our study these solutions corresponded to: 
– Solution A = extract solution. 
– Solution B = Spiked sample with an endotoxin concentration of 0.05 UI/mL. 
– Solution C = standard endotoxin solution at the concentrations of 0.5 IU/mL, 0.005 
IU/mL and 0.005 IU/mL. 
– Solution D = extraction solution (Negative control); the Water for BET is not analyzed 
itself, because it is used to prepare the extraction solution. 
As provided in EP, the test solution was considered free of interfering factors, if, the 
measured concentration of Spiked sample, was within 50-200 per cent of the known 
added endotoxin concentration (0.05 UI/mL), after subtraction of any endotoxin detected 
in the other two wells without added endotoxin (18). 
The test was considered as acceptable if the solutions A (Fig. 11) and C have an endotoxin 
concentration lower than quantification limit (QL), i.e. the lowest endotoxin 
concentration of the standard curve (0.005 UI/mL). 
 
Figure 13 - GFF after extraction (Solution A): 
On the left filter after orbital shaking, on the right filter centrifugation. 
 
The second test provided the contamination of the filter with a kwon amount of standard 
endotoxin equal to the middle concentration of the standard curve and the immediately 
treatment of the matrix with the planned extraction parameters; thus, the endotoxin-free 
Glass 
fibers 
Extract 
 
GFF 
Supernatant 
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water or LAL reagent water (LRW) of the standard endotoxin solution had not the time to 
evaporate and we could, actually, evaluate the endotoxins release from filters in 
extraction solution.  
The test shall carry on also on a Negative control (see above) and on a Positive control, i.e. 
extraction solution, added with an endotoxin concentration equal to or near the middle 
of the standard curve (0.05 UI/mL) and treated with the same extraction conditions 
provided for filters; the Positive control allowed to assess the compatibility of the 
extraction conditions (especially shaking and centrifugation processes) with endotoxins. 
The endotoxin release was calculated as a percentage ratio between endotoxin content of 
the analyzed filter and endotoxin content of the Positive control. 
The validity conditions for this test were: Negative control endotoxin concentration lower 
than quantification limit (0.005 UI/mL), Spiked sample and Positive control endotoxin 
concentration, within 50-200 per cent of the known added endotoxin concentration (0.05 
UI/mL) and an endotoxin release for filters within 75-133 per cent and within 50-200 per 
cent for no more than one test. 
In order to verify the absence of endotoxin irreversible absorption by GFF after sampling, 
we contaminated the latter with the minimum feasible volume of a known amount of 
standard endotoxin equal to the middle concentration of the standard curve (0.05 UI/mL) 
and then we left the filter to dry under a laminar flow hood (Fig. 14); in this way, the little 
LRW amount of the standard endotoxin solution can quickly evaporate in a 
microbiological controlled situation and the endotoxins remained can mime the presence 
of dry airborne endotoxins on the filter. 
  
 
Figure 14 - Drying of endotoxin contaminated GFF under a laminar flow hood 
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Hereinafter the same filter was inserted in the air sampler and an air sampling of 50 
minutes, following EN 14031 provided conditions, was leaded under a laminar flow hood 
(Fig. 15). 
Thus, it is possible to verify if the airborne endotoxins can be irreversibly adsorbed on 
glass fiber during the air passage through the filter in an active air sampling. 
 
 
Figure 15 - Active air sampling under a laminar flow hood with endotoxin cantaminated filter. 
 
Lastly the so treated filter was extracted (Sample) and analyzed. 
This time the Negative control was constituted of a non-contaminated filter, treated in 
the same way of the contaminated one, in order to verify the absence of external 
endotoxin contamination, during the procedures. 
The Positive control was the extraction solution added with an endotoxin concentration 
equal to or near the middle of the standard curve (0.05 UI/mL) and treated with the same 
extraction conditions provided for filters. 
Since the standard endotoxin contained in the Positive control solution did not undergo 
the same processes as that of the Sample, the endotoxin release is calculated as a 
percentage ratio between endotoxin content of the Sample and theoretical endotoxin 
concentration with which the filter has been contaminated, i.e. the middle concentration 
of the standard curve (0.05 UI/mL). 
The validity conditions for this test were: Negative control endotoxin concentration lower 
than quantification limit (0.005 UI/mL), Spiked sample and Positive control endotoxin 
concentration, within 50-200 per cent of the known added endotoxin concentration (0.05 
UI/mL) and an endotoxin release for filters within 50-200 per cent. 
Laminar 
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GFF 
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In order to conduct an endotoxin test holding time assessment, the presence of airborne 
endotoxins on filter after air sampling was rebuild as described in the third test; the 
contaminated filters were stored in selected conditions and, then, extracted and 
analyzed, at least, in four different times (minimum time period: 24 h). 
The validity conditions for this test were the same as those for the third test. 
Experimental specific parameters of each test conducted were detailed Section 9.1. 
 
5.2 Results 
The experimental results are shown in the tables below. 
 
Assesment of  the  filter compatibility with test of bacterial endotoxins  
Initially, Kinetic Chromogenic LAL test technique as BET and an 0.05% aqueous solution of 
Tween 20 as extraction solution were used.  
Cartridges with four wells pre-filled with lyophilized  LAL reagent, two of which added of a 
CSE amount equal to the middle concentration of the pre-calibrated standard curve 
(Spiked sample channels), were employed, allowing to reduce the opportunity for 
technician error and to eliminate the preparation of LAL reagent solution, standard curve 
and spiked samples. 
Already known experimental laboratory data about the absence of interference with 
kinetic chromogenic cartridges and the increase of endotoxins recovering for swabs of an 
0.05% aqueous solution of Tween 20  existed; therefore, the latter was employed instead 
of the LAL reagent water (LRW) suggested by EN 14031. 
 
Table 3 -Test conducted as expected 
  
Sample
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Spiked sample 
recovery                    
(%)
Outcame
Negative control < 0.005 IU/mL < 0.005 IU/mL 117% C
Test N° 1 0.006 IU/mL < 0.005 IU/mL 80% C
Test N° 2 >0.500 IU/mL < 0.005 IU/mL UNDEFINED NC
Test N° 3 >0.500 IU/mL < 0.005 IU/mL UNDEFINED NC
QL = 0.005 IU/mL                                            C= Compliant                                            NC = Not Compliant
37 
 
Extract interfered with the BET probably activating the reagent and so enhancing 
endotoxins recovery above acceptance limits.  
In this case we planned to change the filter (see Fig. 11), however, we decided to 
investigate the cause of this interference before giving up GFF. 
In order to verify if the glass fibers of the filters  adsorb at the same wavelength at which 
the release of the chromophore (p-nitroanilina) of LAL reagent is detected (450 nm), we 
performed a spectroscopic test in the range of UV/visible wavelength on the extract (see 
Appendix 2 for more experimental details). The test results did not show the presence of 
substances in extraction solution that adsorb light in the range of interest.  
Then we decided to follow the indications given by EN 14031 and replace the 0.05% 
aqueous solution of Tween 20 with LRW, assuming that, probably, the interaction 
between glass fibers of the filter and the aqueous solution of Tween caused the 
interference; also in this case, the results showed a little interference so we chose to 
dilute 1=>10 with LRW the extract before analyzing it. For the calculation of the MVD see 
Appendix 3. 
 
Table 4 - Tests conducted samples dilution ratio of 1=>10 with LRW 
 
The test solution was considered free of interfering factors, therefore, for the next 
validation steps, the extraction solution shall be LRW and the extract shall be diluted 1 => 
10 with LRW. 
  
Sample
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Spiked sample 
recovery                    
(%)
Outcame
Negative control < 0.005 IU/mL < 0.005 IU/mL 96% C
Test N° 1 < 0.005 IU/mL < 0.005 IU/mL 95% C
Test N° 2 < 0.005 IU/mL < 0.005 IU/mL 128% C
Test N° 3 < 0.005 IU/mL < 0.005 IU/mL 124% C
QL = 0.005 IU/mL                                            C= Compliant                                            NC = Not Compliant
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Assesment of the filter’s ability to release adsorbed endotoxins in the extraction 
solution  
 
Table 5 - Tests conducted as expected,  
but with the aforementionedextraction parameters modifictions 
 
The good results allowed to proceed to the next validation step, without any change. 
 
Assessment of the absence of irreversible adsorption of bacterial endotoxins by the 
filter  
 
Table 6 - Tests conducted as expected, 
 but with the aforementioned extraction parameters modification 
The endotoxin release was not acceptable, because was below 50 per cent of theoretical 
endotoxin concentration with which the filter has been contaminated, i.e. the middle 
concentration of the standard curve (0.05 UI/mL). 
Although in case of failure of the test we provided to change filter, believing in the quality 
of the filter, we chose to use the kinetic turbidimetric method as BET, repeating all tests 
again. We decided to use a 0.05% aqueous solution of Tween 20 extraction solution, as 
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Spiked sample 
recovery                     
(%)
Endotoxin 
release                      
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL 113% = C
0.039 IU/mL 0.050 IU/mL 107% 78% C
0.043 IU/mL 0.039 IU/mL 152% 110% C
0.048 IU/mL 0.039 IU/mL 189% 123% C
0.053 IU/mL 0.039 IU/mL 128% 136% C
Negative control
Positive  control
Test N° 1
Test N° 2
Test N° 3
Sample
QL = 0.005 IU/mL                                                     C= Compliant                                                     NC = Not Compliant
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Spiked sample 
recovery                     
(%)
Endotoxin in 
release                      
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL 100% = C
Test N° 1 0.052 IU/mL 0.050 IU/ml 90% 104% C
Test N° 2 0.053 IU/mL 0.050 IU/ml 124% 106% C
Test N° 3 0.047 IU/mL 0.050 IU/ml 87% 94% C
Test N° 1 0.032 IU/mL 0.050 IU/ml 122% 64% C
Test N° 2 0.020 IU/mL 0.050 IU/ml 118% 40% NC
Test N° 3 0.020 IU/mL 0.050 IU/ml 128% 40% NC
QL = 0.005 IU/mL                                                     C= Compliant                                                     NC = Not Compliant
Sample
Negative control
Positive  
control
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originally envisaged for the validation, and to experience a 1=>2 (see Appendix 3 for 
more details) dilution with LRW (see Section 9.2 for more experimental details).    
Assesment of  the filter compatibility with test of bacterial endotoxins  
 
Table 7 - Tests conducted as expected 
 
Assesment of the filter’s ability to release adsorbed endotoxins in the extraction 
solution  
 
Table 8 - Test conducted as expected 
 
 
Endotoxin 
Concentration 
(IU/mL)
Spiked sample 
recovery                     
(%)
Outcame
< 0.005 IU/mL = C
< 0.005 IU/mL = C
< 0.005 IU/mL 192% C
< 0.005 IU/mL 177% C
< 0.005 IU/mL 174% C
Test N° 1
Test N° 2
Test N° 3
QL = 0.005 IU/mL                          C= Compliant                           NC = Not Compliant
Sample
Negative 
control
Tween 20 
0.05%
LRW
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.085 IU/mL 0.050 IU/mL 170% C
0.095 IU/mL 0.085 IU/mL 112% C
0.100 IU/mL 0.085 IU/mL 118% C
0.095 IU/mL 0.085 IU/mL 112% C
Test N° 1
Test N° 2
Test N° 3
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
Sample
Negative 
control
Tween 20 
0.05%
LRW
Positive control
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Assessment of the absence of irreversible adsorption of bacterial endotoxins by the 
filter  
 
Table 9 - Tests conducted as expected 
 
Evaluation of endotoxins holding time by filters 
Initially we decided to store the contaminated  filter in refrigerator (2÷8 °C), because 
already known laboratory experimental data suggest the stability of endotoxins at such 
temperature: for example, the solution of standard endotoxin is stored in refrigerator 
(2÷8 °C) for a maximum of 14 days. 
 
Table 10 - Tests conducted as expected 
 
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.085 IU/mL 0.050 IU/mL 170% C
0.047 IU/mL 0.050 IU/mL 94% C
0.038 IU/mL 0.050 IU/mL 76% C
0.042 IU/mL 0.050 IU/mL 84% C
Test N° 1
Test N° 2
Test N° 3
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
Sample
Negative 
control
Tween 20 
0.05%
LRW
Positive control
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.070 IU/mL 0.050 IU/mL 140% C
Test N° 1 0.039 IU/mL 0.050 IU/mL 78% C
Test N° 2 0.039 IU/mL 0.050 IU/mL 78% C
Test N° 3 0.040 IU/mL 0.050 IU/mL 80% C
Sample
Negative 
control
Tween 20 
0.05%
LRW
Positive control
t = 0
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
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Table 11 -Tests conducted as expected after 1 day of refrigerated storage 
 
Table 12 - Tests conducted as expected after 2 days of refrigerated storage 
 
Table 13 - Tests conducted as expected after 3 days of refrigerated storage 
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.070 IU/mL 0.050 IU/mL 140% C
Test N° 1 0.022 IU/mL 0.050 IU/mL 44% NC
Test N° 2 0.016 IU/mL 0.050 IU/mL 32% NC
Test N° 3 0.018 IU/mL 0.050 IU/mL 36% NC
t = 1 day
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
Positive control
Sample
Negative 
control
Tween 20 
0.05%
LRW
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.070 IU/mL 0.050 IU/mL 140% C
Test N° 1 0.044 IU/mL 0.050 IU/mL 88% C
Test N° 2 0.027 IU/mL 0.050 IU/mL 54% C
Test N° 3 0.022 IU/mL 0.050 IU/mL 44% NC
Positive control
t = 2 days
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
Sample
Negative 
control
Tween 20 
0.05%
LRW
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.070 IU/mL 0.050 IU/mL 140% C
Test N° 1 0.023 IU/mL 0.050 IU/mL 46% NC
Test N° 2 0.024 IU/mL 0.050 IU/mL 48% NC
Test N° 3 0.022 IU/mL 0.050 IU/mL 44% NC
Positive control
t = 3 days
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
Sample
Negative 
control
Tween 20 
0.05%
LRW
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Table 14 - Tests conducted as expected after 5 days of refrigerated storage 
 
The endotoxin release did not satisfy the acceptance criteria when the storage is 
conducted in refrigerator (at 28 °C), since it generated a decay of endotoxin title already 
after the first day.  
Then, we decided to repeat the holding time tests, storing the contaminated filters in 
freezer (- 80±5°C). 
 
Table 15 - Tests conducted as expected 
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.070 IU/mL 0.050 IU/mL 137% C
Test N° 1 0.020 IU/mL 0.050 IU/mL 40% NC
Test N° 2 0.018 IU/mL 0.050 IU/mL 36% NC
Test N° 3 0.019 IU/mL 0.050 IU/mL 38% NC
Positive control
t = 5 days
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
Sample
Negative 
control
Tween 20 
0.05%
LRW
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.068 IU/mL 0.050 IU/mL 136% C
Test N° 1 0.038 IU/mL 0.050 IU/mL 76% C
Test N° 2 0.041 IU/mL 0.050 IU/mL 82% C
Test N° 3 0.041 IU/mL 0.050 IU/mL 82% C
Sample
Negative 
control
Tween 20 
0.05%
LRW
Positive control
t = 0
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
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Table 16 - Tests conducted as expected after 1 day of freezing storage 
 
Table 17 - Tests conducted as expected after 2 days of freezing storage 
 
 
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.068 IU/mL 0.050 IU/mL 136% C
Test N° 1 0.043 IU/mL 0.050 IU/mL 86% C
Test N° 2 0.042 IU/mL 0.050 IU/mL 84% C
Test N° 3 0.039 IU/mL 0.050 IU/mL 78% C
Sample
Negative 
control
Tween 20 
0.05%
LRW
Positive control
t = 1 day
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.068 IU/mL 0.050 IU/mL 136% C
Test N° 1 0.046 IU/mL 0.050 IU/mL 92% C
Test N° 2 0.046 IU/mL 0.050 IU/mL 92% C
Test N° 3 0.049 IU/mL 0.050 IU/mL 98% C
Sample
Negative 
control
Tween 20 
0.05%
LRW
Positive control
t = 2 days
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
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Table 18 - Tests conducted as expected after 3 days of freezing storage 
Table 19 - Tests conducted as expected after 4 days of freezing storage 
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.068 IU/mL 0.050 IU/mL 136% C
Test N° 1 0.034 IU/mL 0.050 IU/mL 68% C
Test N° 2 0.035 IU/mL 0.050 IU/mL 70% C
Test N° 3 0.036 IU/mL 0.050 IU/mL 72% C
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
Negative 
control
t = 3 days
Sample
Tween 20 
0.05%
LRW
Positive control
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.068 IU/mL 0.050 IU/mL 136% C
Test N° 1 0.048 IU/mL 0.050 IU/mL 96% C
Test N° 2 0.041 IU/mL 0.050 IU/mL 82% C
Test N° 3 0.037 IU/mL 0.050 IU/mL 74% C
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
Sample
Negative 
control
Tween 20 
0.05%
LRW
Positive control
t = 4 days
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Table 20 - Tests conducted as expected after 10 days of freezing storage 
The results are acceptable until 4 days of filters freezing storage. 
 
5.3 Discussion 
The kinetic colorimetric method did not allow to recover dried endotoxins on the glass 
fiber filters, presumably because the reagent volume is not sufficient to neutralize 
interference caused by the interaction between glass fiber of filters and Tween 20.  
The glass fiber filter did not show interference with kinetic turbidimetric method and the 
latter allowed endotoxins to be recovered not only in the solution but also if absorbed on 
the matrix, using an extraction solution of  an 0.05% aqueous solution of Tween 20. 
For this reason glass fiber filters were considered able to recover airborne endotoxins and 
the use of the kinetic turbidimetric method as BET together with the 0.05% aqueous 
solution of Tween 20 as extraction solution were considered the suggested conditions for 
the aforementioned recovery. 
The results of the filters storage in refrigerator (28 ° C) showed a decay of the title of 
endotoxins neither uniform nor constant (Fig. 16):  
Endotoxin 
Concentration 
(IU/mL)
Theoretical 
Endotoxin 
Concentration 
(IU/mL)
Endotoxin 
release 
(%)
Outcame
< 0.005 IU/mL < 0.005 IU/mL = C
< 0.005 IU/mL < 0.005 IU/mL = C
0.068 IU/mL 0.050 IU/mL 136% C
Test N° 1 0.012 IU/mL 0.050 IU/mL 24% NC
Test N° 2 0.014 IU/mL 0.050 IU/mL 28% NC
Test N° 3 0.015 IU/mL 0.050 IU/mL 30% NC
t = 10 days
QL = 0.005 IU/mL                                       C= Compliant                                        NC = Not Compliant
Sample
Negative 
control
Tween 20 
0.05%
LRW
Positive control
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Figure 16 - Filter holding time: day  results of endotoxin release in storage refrigerating conditions 
The freeze storage, indeed, allowed a steady recovery of the endotoxins, without showing 
any decay of the title until the fourth day of storage (Fig. 17): 
 
Figure 17 - Filter holding time: day results of endotoxin release in storage freezing conditions 
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According to the UNI EN 14031:2005, the developed method for recovering airborne 
endotoxins provided: 
- air sampling at a rate of 2 l/min conducted by filtration through a depyrogenated glass 
fiber filter (7 mm and a nominal pore size of 0.3 μm). 
- eventual filter storage in freezer (- 80±5 °C) for a maximum time of 4 days. 
- filter extraction  in 10 mL of 0.05% aqueous solution of Tween 20 by stirring with 
orbital shaker at a speed rotation of 250 rpm for one hour and centrifuging at 1000g 
for 15 minutes. 
- supernatant dilution 1 => 2 with endotoxinfree LAL Reagent Water (LRW). 
- kinetic turbidimetric LAL test as BET. 
- expression of airborne endotoxin results in IU/m3. 
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6. Development of a method for assessing environmental 
contamination of Gram negative bacteria   
 
6.1 Description 
In addition to the quantification of airborne endotoxins, we decided to detect the 
presence of an objectionable past or current Gram negative bacteria environmental 
contamination in production environments of injectable drugs, in order to assess an 
eventual correlation of them with airborne endotoxins. 
In order to monitor the Gram-negative bacteria environmental  contamination, we 
followed indications given by EU GMP in Annex 1 (24) and, therefore, we used settling 
plates (Ø 90 mm) for passive air sampling and contact plates (Ø 55 mm) for  surface  
sampling. 
We chose a selective medium for the growth of such bacteria, i.e. the Violet Red Bile 
Glucose Agar (VRBGA); to ensure the reliability of the microbial test, it was necessary to 
conduct Growth promotion test (GPT) on the media, with Pseudomonas aeruginosa and 
Escherichia coli as provided in European Pharmacopoeia (36). 
As specified in European Pharmacopoeia, in order to inactivate antimicrobial agents 
(disinfectants) eventually present on the surfaces,  we added the medium with a 
neutralizing  agent (Tween 80) (35) (Fig. 18). 
 
Figure 18 - Open contact plate with VRBGA - Tween 80 medium 
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Since in Pharmacopoeia is not specified the amount of neutralizing agent to add, we 
chose a concentration that does not cause problems in other used medium. To ensure the 
neutralizing agent’s efficiency and absence of toxicity for microorganism, we carried out a 
growth promotion test on the medium challenged using two different type of quaternary 
ammonium cation disinfectants (QACs) (35); a blank with neutralizer and without 
disinfectant shall also carry out (see Section 9.3 for more experimental details). 
The acceptance criteria provide a recovery in the range of  50-200% calculated as a 
percentage ratio between the number of colony of Escherichia coli and Pseudomonas 
aeruginosa counted in in VRBGA (TSA) and those present on a non selective medium 
Soybean Casein Digest Agar. 
6.2 Results 
 
In the Table 21 are reported the GPT results on VRBGA for settling plates. 
 
 
Table 21 - GPT results on VRBGA for settling plates 
In the Table 22 are reported the GPT results on VRBGA for contact plates: 
 
Table 22 -  GPT results on VRBGA for contact plates 
Bacterial test 
strains
Ammount of 
inoculum                     
(L)
Number of 
colinies on TSA 
(cfu/plate)
Numbers of 
colonies on 
VRBGA 
(cfu/plate)
Colonies 
recovery                      
(%)
Outcame
Escherichia                          
coli
100 88 97 110% C
Pseudomonas 
aeruginosa
100 90 92 102% C
C= Compliant                                                                                                                           NC = Not Compliant
Bacterial test 
strains
Ammount of 
inoculum                     
(L)
Number of 
colinies on TSA 
(cfu/plate)
Numbers of 
colonies on 
VRBGA 
(cfu/plate)
Colonies 
recovery                      
(%)
Outcame
Escherichia                          
coli
100 78 96 123% C
Pseudomonas 
aeruginosa
100 80 85 106% C
C= Compliant                                                                                                                           NC = Not Compliant
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In Table 23 and 24 are reported the GPT results on VRBGA for contact plates challenged 
using the two  type of QACs.  
 
Table 23 - GPT results on VRBGA for contact plates challenged using the first type of QACs 
Tabella 24 - GPT results on VRBGA for contact plates challenged using the second type of QACs 
 
In Figure 19 are shown the photos of the contact plates incolulated with the 
microorganisms and challenged with one type of detergent; as we can see, the 
Escherichia coli  grew acidifying the medium, which veers towards a more pinkish color. 
 
Figure 19 –GPT results on VRBGA for contact plates challenged using the first type of QACs 
  
Bacterial test 
strains
Ammount of 
inoculum                     
(L)
Number of 
colinies on TSA 
(cfu/plate)
Numbers of 
colonies on 
VRBGA 
(cfu/plate)
Colonies 
recovery                      
(%)
Outcame
Escherichia                          
coli
100 88 87 97% C
Pseudomonas 
aeruginosa
100 90 70 79% C
C= Compliant                                                                                                                           NC = Not Compliant
Bacterial test 
strains
Ammount of 
inoculum                     
(L)
Number of 
colinies on TSA 
(cfu/plate)
Numbers of 
colonies on 
VRBGA 
(cfu/plate)
Colonies 
recovery                      
(%)
Outcame
Escherichia                          
coli
100 88 60 68% C
Pseudomonas 
aeruginosa
100 90 54 60% C
C= Compliant                                                                                                                           NC = Not Compliant
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6.3 Discussion 
 
The results of the microbial tests demonstrated that the VRBGA was suitable for the 
growing of Gram negative bacteria. 
The medium composition of the contact plates was capable of efficiently neutralizing our 
disinfectants without any worsening in its efficiency. 
Finally, the method for monitoring Gram negative bacterial environmental contamination 
provides: 
- the use of settling plates with a selective medium (VRBGA) left open for two hours for 
sampling airborne Gram-negative bacteria. 
- the use of contact plates filled with a selective medium (VRBGA) added with 3% of 
Tween 80 for sampling of Gram-negative bacteria on the surfaces. 
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7. Environmental monitoring of injectable drugs clean areas  
7.1 Description 
In this part of the study we proposed to establish levels of airborne endotoxins and Gram-
negative bacteria in production environment of injectable drugs and to evaluate whether 
the level of airborne bacterial endotoxins may represent a real risk for the pharmaceutical 
products processed therein, i.e. a potentiality of producing products that do not comply 
with the specifications and the defined quality requirements. 
First we identified the injectable drugs production areas where there are more possible 
sources of Gram-negative bacteria contamination during manufacturing processes 
manipulation.  
We chose, therefore, the three rooms where a wide use of water occurs: products 
solutions and materials preparation rooms and washing area for vials. 
The room in which there is the vials washing machine is classified as a Grade D clean area 
according EU –GMP annex 1 , (the vials filling occurs in separated aseptic area); there, the 
open vials stay in contact with the environment only before entering the machine, 
whereas all the washing and drying operations occur inside the fully closed machinery. 
The rooms for product solutions and material preparation  are classified as Grade C clean 
areas, according EU –GMP annex 1, in the first case the product is directly exposed to the 
surrounding environment during the loading of dissolutors, while, in the second one only 
materials that will be in contact with the product (e.g. tubes) are exposed to the 
surrounding environment during the washing, drying and wrapping . 
 
The selection of sampling locations was made identifying: 
- The sites from which germs can be transferred in the product or in other clean rooms 
with low probability as a result of turbulence, but in which there can be a grate 
contamination, representing a microbiological load (e.g. sinks, doors, workbenches). 
- The sites from which the germs can be transferred with high probability in the 
product, as a result of turbulence (e.g. near dissolvers or product tanks).  
- The sites where the transit of the vials during filling operation, of the personnel and 
of the carts is focused (e.g. exit of vials, autoclave). 
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- The sites where activity is concentrated at the beginning and end of the day (hood 
and console of the vials washing machine, sampling points of WFI system). 
The chosen minimum number of sampling locations (N) was N=√S, as suggested by 
EN/ISO 14644-1/2 for clean room classification, where S is the surface (m2) of the room. 
Therefore N is respectively equal to 6 for the grade C rooms and to 11 for the grade D 
room. 
We arbitrary chose a number of 3  4 air samples are per room. 
Microbiological environmental controls were conducted in triplicate per room, in order to 
assess the variability of the data and obtain reasonable assurance that the result was not 
due to chance or luck, and in operational condition, avoiding to prejudice the nutritional 
properties of the medium and preventing any accidental contamination. 
In order to quantify airborne endotoxins, the dynamic air sampling and the samples’ 
analysis were constructed according to the aforementioned developed method for 
recovering airborne endotoxins. 
From LAL test results, the concentration of airborne endotoxins was calculated with the 
follow equation: 
CA = [(CL × V0 × d) / (Q × t)] × 103 
- CA: airborne enedotoxins concentration  (IU/m3)  
- V0 : extraction solution volume (mL) 
- CL: endotoxin concentration measured with LAL test (IU/mL) 
- t: sampling length (min) 
- Q: sampler airflow speed (m3/min) 
- d: extraction dilution ratio 
- Q x t: air volume sampled (m3)  
The static sampling for the detection of airborne Gram-negative bacteria lasted two 
hours. 
For surfaces sampling contact plates were applied on the floor or on the walls, imparting 
a moderate pressure for 10 seconds (see more experimental details in Section 9.3). 
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The bacterial colonies count was carried out after the incubation of the plates at 30-35 °C 
for 3 days and we considered as the alert limit values 10 times inferior than those 
reported in EU-GMP annex 1 (see Tab. 2). 
7.2 Results 
The experimental results of the environmental monitoring are shown in the tables below 
and for more experimental details see Section 9.3. 
 
Table 25 - Airborne endotoxins concentration in solutions preparation room-E1 (Grade C) 
 
M
o
n
it
o
ri
n
g
Endotoxin 
Concentration 
(IU/mL)
Sample           
spike                       
(%)
Airborn 
Endotoxin 
concentration 
(IU/mL)
Outcame
0.006 IU/mL 165% 1,2 IU/m3 C
< QL 154% < 1 IU/m3 C
< QL 167% < 1 IU/m3 C
< QL 158% < 1 IU/m3 C
Tween 20 
0.05%
< 0.005 IU/mL NP = C
LRW < 0.005 IU/mL = = C
< QL NP < 1 IU/m3 C
< QL NP < 1 IU/m3 C
< QL NP < 1 IU/m3 C
< QL NP < 1 IU/m3 C
Tween 20 
0.05%
< 0.005 IU/mL 153% = C
LRW < 0.005 IU/mL = = C
< QL 165% < 1 IU/m3 C
< QL 154% < 1 IU/m3 C
< QL 167% < 1 IU/m3 C
< QL 158% < 1 IU/m3 C
Tween 20 
0.05%
< 0.005 IU/mL 193% = C
LRW < 0.005 IU/mL = = C
Sample
A E1 3
A E1 1
Negative 
control
A E1 4
A E1 3
A E1 4
N° 1
QL = 0.005 IU/mL               NP = Not performed               C= Compliant               NC = Not Compliant
N° 2
A E1 1
A E1 2
Negative 
control
N° 3
A E1 1
A E1 2
A E1 3
A E1 4
A E1 2
Negative 
control
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Table 26 - Airborne Gram-negative bacteria in solutions preparation room-E1 (Grade C)  
 
 
Table 27 - Gram-negative bacteria on surfaces in solutions preparation room-E1 (Grade C) 
 
 
M
o
n
it
o
ri
n
g
Sampling location
Settling              
plates (cfu/plate)
Settling            
plates             
(cfu/4h)
A E1 1 0 < 2
A E1 2 0 < 2
A E1 3 0 < 2
A E1 4 0 < 2
A E1 1 0 < 2
A E1 2 0 < 2
A E1 3 0 < 2
A E1 4 0 < 2
A E1 1 0 < 2
A E1 2 0 < 2
A E1 3 0 < 2
A E1 4 0 < 2
N° 1
N° 2
N° 3
CR = Contable range = 100 cfu/plate  -  Alert limit= 5 cfu/plate  -  Action limit= 50 cfu/plate
Monitoring
Sampling 
location
Contat    
plates 
(cfu/plate)
Monitoring
Sampling 
location
Contat    
plates 
(cfu/plate)
Monitoring
Sampling 
location
Contat    
plates 
(cfu/plate)
Pv E1 1 0 Pv E1 1 0 Pv E1 1 0
Pv E1 2 0 Pv E1 2 0 Pv E1 2 0
Pv E1 3 1 Pv E1 3 0 Pv E1 3 1
Pv E1 4 SC Pv E1 4 0 Pv E1 4 0
Pv E1 5 1 Pv E1 5 0 Pv E1 5 1
Pv E1 6 0 Pv E1 6 0 Pv E1 6 0
Pv E1 7 0 Pv E1 7 1 Pv E1 7 0
Pv E1 8 1 Pv E1 8 0 Pv E1 8 0
Pv E1 9 0 Pv E1 9 0 Pv E1 9 0
Pv E1 10 0 Pv E1 10 0 Pv E1 10 0
N° 1 N° 2 N° 3
SC = Swarming Colonies      -     CR = Contable range = 100 cfu/plate     -     Alert limit = 3 cfu/plate     -     Action limit = 25 cfu/plate 
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Table 28 - Airborne endotoxins concentration in solutions preparation room-E2 (Grade C) 
 
 
M
o
n
it
o
ri
n
g
Endotoxin 
Concentration 
(IU/mL)
Sample           
spike                       
(%)
Airborn 
Endotoxin 
concentration 
(IU/mL)
Outcame
< QL 153% < 1 IU/m3 C
< QL NP < 1 IU/m3 C
< QL NP < 1 IU/m3 C
Tween 20 
0.05%
< 0.005 IU/mL NP = C
LRW < 0.005 IU/mL = = C
< QL 148% < 1 IU/m3 C
< QL 165% < 1 IU/m3 C
< QL 146% < 1 IU/m3 C
Tween 20 
0.05%
< 0.005 IU/mL NP = C
LRW < 0.005 IU/mL = = C
< QL NP < 1 IU/m3 C
< QL NP < 1 IU/m3 C
< QL NP = C
Tween 20 
0.05%
< 0.005 IU/mL 193% = C
LRW < 0.005 IU/mL = = C
Sample
N° 1
A E2 3
Negative 
control
Negative 
control
N° 2
A E2 1
A E2 2
A E2 3
A E2 1
A E2 2
A E2 1
A E2 2
A E2 3
Negative 
control
QL = 0.005 IU/mL               NP = Not performed               C= Compliant               NC = Not Compliant
N° 3
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Table 29 - Airborne Gram-negative bacteria in solutions preparation room-E2 (Grade C)  
 
 
Table 30 - Gram-negative bacteria on surfaces in solutions preparation room-E2 (Grade C) 
 
 
 
 
M
o
n
it
o
ri
n
g
Sampling location
Settling              
plates (cfu/plate)
Settling            
plates             
(cfu/4h)
A E2 1 0 < 2
A E2 2 0 < 2
A E2 3 0 < 2
A E2 1 0 < 2
A E2 2 0 < 2
A E2 3 0 < 2
A E2 1 0 < 2
A E2 2 0 < 2
A E2 3 0 < 2
CR = Contable range = 100 cfu/plate  -  Alert limit= 5 cfu/plate  -  Action limit= 50 cfu/plate
N° 2
N° 3
N° 1
Monitoring
Sampling 
location
Contat    
plates 
(cfu/plate)
Monitoring
Sampling 
location
Contat    
plates 
(cfu/plate)
Monitoring
Sampling 
location
Contat    
plates 
(cfu/plate)
Pv E2 1 1 Pv E2 1 0 Pv E2 1 0
Pv E2 2 5 Pv E2 2 0 Pv E2 2 1
Pv E2 3 0 Pv E2 3 0 Pv E2 3 4
Pv E2 4 1 Pv E2 4 0 Pv E2 4 3
Pv E2 5 2 Pv E2 5 SC Pv E2 5 0
Pv E2 6 1 Pv E2 6 0 Pv E2 6 10
Pv E2 7 0 Pv E2 7 0 Pv E2 7 0
Pv E2 8 0 Pv E2 8 0 Pv E2 8 6
N° 1
SC = Swarming Colonies      -     CR = Contable range = 100 cfu/plate     -     Alert limit = 3 cfu/plate     -     Action limit = 25 cfu/plate 
N° 2 N° 3
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Table 31 - Airborne endotoxins concentration in solutions preparation room-E4 (Grade D) 
 
 
M
o
n
it
o
ri
n
g
Endotoxin 
Concentration 
(IU/mL)
Sample           
spike                       
(%)
Airborn 
Endotoxin 
concentration 
(IU/mL)
Outcame
< QL 158% < 1 IU/m3 C
< QL 171% < 1 IU/m3 C
< QL 149% < 1 IU/m3 C
Tween 20 
0.05%
< 0.005 IU/mL = = C
LRW < 0.005 IU/mL = = C
< QL NP < 1 IU/m3 C
< QL NP < 1 IU/m3 C
< QL NP < 1 IU/m3 C
Tween 20 
0.05%
< 0.005 IU/mL = = C
LRW < 0.005 IU/mL = = C
< QL NP < 1 IU/m3 C
< QL NP < 1 IU/m3 C
< QL NP < 1 IU/m3 C
Tween 20 
0.05%
< 0.005 IU/mL 193% = C
LRW < 0.005 IU/mL = = C
Sample
N° 1
A E4 1
A E4 2
A E4 3
Negative 
control
QL = 0.005 IU/mL               NP = Not performed               C= Compliant               NC = Not Compliant
N° 2
A E4 1
A E4 2
A E4 3
Negative 
control
N° 3
A E4 1
A E4 2
A E4 3
Negative 
control
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Table 32 - Airborne Gram-negative bacteria in solutions preparation room-E4 (Grade D) 
 
 
Table 33 - Gram-negative bacteria on surfaces in solutions preparation room-E4 (Grade D) 
 
 
M
o
n
it
o
ri
n
g
Sampling location
Settling              
plates (cfu/plate)
Settling            
plates             
(cfu/4h)
A E4 1 0 < 2
A E4 2 0 < 2
A E4 3 0 < 2
A E4 1 0 < 2
A E4 2 0 < 2
A E4 3 0 < 2
A E4 1 0 < 2
A E4 2 0 < 2
A E4 3 0 < 2
N° 1
N° 2
N° 3
CR = Contable range = 100 cfu/plate  -  Alert limit= 10 cfu/plate  -  Action limit= 100 cfu/plate
Monitoring
Sampling 
location
Contat    
plates 
(cfu/plate)
Monitoring
Sampling 
location
Contat    
plates 
(cfu/plate)
Monitoring
Sampling 
location
Contat    
plates 
(cfu/plate)
Pv E4 1 0 Pv E4 1 0 Pv E4 1 0
Pv E4 2 0 Pv E4 2 6 Pv E4 2 11
Pv E4 3 SC Pv E4 3 SC Pv E4 3 13
Pv E4 4 SC Pv E4 4 2 Pv E4 4 2
Pv E4 5 2 Pv E4 5 19 Pv E4 5 1
Pv E4 6 3 Pv E4 6 9 Pv E4 6 4
Pv E4 7 2 Pv E4 7 21 Pv E4 7 2
Pv E4 8 4 Pv E4 8 6 Pv E4 8 3
Pv E4 9 0 Pv E4 9 0 Pv E4 9 9
Pv E4 10 0 Pv E4 10 0 Pv E4 10 0
Pv E4 11 0 Pv E4 11 20 Pv E4 11 0
Pv E4 12 2 Pv E4 12 7 Pv E4 12 SC
Pv E4 13 SC Pv E4 13 6 Pv E4 13 SC
Pv E4 14 3 Pv E4 14 0 Pv E4 14 0
Pv E4 15 1 Pv E4 15 0 Pv E4 15 1
Pv E4 16 32 Pv E4 16 0 Pv E4 16 0
SC = Swarming Colonies      -     CR = Contable range = 100 cfu/plate     -     Alert limit = 5 cfu/plate     -     Action limit = 50 cfu/plate 
N° 1 N° 2 N° 3
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7.3 Discussion 
The tests conducted in the production environments of injectable drugs revealed the 
presence of detectable amounts of airborne endotoxins but lower than the quantification 
limit of the assay (i.e. 0.005 IU/mL corresponding to 1 IU/m3). 
In the event concentrations of airborne endotoxins exceeding QL were found, we would 
have to assess the risk for the product, creating a model which correlates the exposure 
time and surfaces of the product, materials or vials (depending on the rooms considered) 
to the air with the sedimentation rate of the endotoxins. 
 
Vial airborne Gram-negative bacteria were not detected in any room, while we found 
Gram-negative bacteria on the surfaces. 
Because of the presence of swarming colonies, it was not possible to count some of the 
contact plates; this phenomenon is quite frequent in Gram-negative bacteria and is due 
to the motion of bacteria with flagella or cilia in the surrounding regions of the colony 
which form a visible halo. 
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8. Conclusion 
Starting from the European standard  UNI EN 14031:2005, we have succeeded to develop 
an efficient and reproducible validated method  for recovering airborne endotoxins. 
This method was successfully employed in the aim of quantify airborne endotoxins in 
Abiogen Pharma’s production environments of injectable drugs. 
 
Additionally, the development of a validated method for assess Gram-negative bacteria 
environmental contamination allowed us to evaluate whether an early detection of such 
objectionable microorganisms by a test in near real time could be possible. 
 
 The detection of amounts of airborne endotoxins lower than the quantification limit of 
the assay (i.e. 0.005 IU/mL corresponding to 1 IU/m3) and far inferior to the Health -based 
Occupational Exposure Limit (HBROEL = 90 UI/m38h) permitted to conclude that in  the 
aforementioned environments airborne endotoxins do not represent a risk neither for the 
parenteralproducts processed herein nor for the workers’ health. 
 
The finding of vial Gram negative bacteria only on the surfaces of the clean rooms and not 
in the air could represent an early warning of a presumed correlation with the low 
amounts of airborne endotoxins. 
However, further tests should be conducted to guarantee this relationship. 
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9. Experimental protocols 
9.1. Validation of the method for recovering airborne endotoxins 
 In this section, the materials and the experimental parameters employed in the 
validation of the method for recovering airborne endotoxins are explained; all the tests 
are conducted in triplicate. 
Materials 
- LAL Portable Test System and Multi Cartridge Reader 
- Vortex mixer 
- Gilson type pipettes 
- LAL materials in borosilicate depyrogenated glass: Test tubes 18 x 150 mm, glass 
pipettes, 25 mL beakers 
- Cartridge (0.5 - 0.005 IU/mL) 
- Sterile Petri dishes in polystyrene  
- Refrigerator (2 to 8 ° C) 
- Freezer (- 80 ± 5 ° C) 
- Depyrogenated stainless steel scissors  
- LAL Reagent Water (LRW) 
- Tween 20 
- Timer 
- Standard Endotoxin (CSE BRP) 
- Air Sampler 
- Flowmeter 
- Filter Holder 
- Support for sampler 
- Glass Fiber Filter (GFF) GF / 1 Ø 37 mm 
- Cellulose pad Ø 37 mm 
- Orbital Shakers 
- Depyrogenated stainless steel pliers  
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Assessment of  the  filter compatibility with test of bacterial endotoxins 
Depyrogenate filters, scissors and pliers at 220 ° C for 3 hours, i.e. following a dry heat 
treatment validated for the reduction of the endotoxin content of at least 3 log units 
Cut the filter into 4 pieces and place it into a beaker together with 5 mL of an 0.05% 
aqueous solution of Tween 20. 
Cover the beaker with parafilm and shake it with orbital shaker at room temperature for 
60 minutes at 250 rpm in one direction only. 
Centrifuge the solution for 15 minutes at 1000 g to eliminate the residues of glass fiber; 
recover the supernatant and analyze it with Chromogenic kinetic LAL test Cartridge ( = 
0.005 IU / mL). 
Carry out LAL test also on a Negative control, i.e. a 5 mL 0.05%, aqueous solution of  
Tween 20, which has undergone the same extraction treatment of the sample. 
 
Assesment of the filter’s ability to release adsorbed endotoxins in the extraction 
solution  
Depyrogenate filters, scissors and pliers at 220 ° C for 3 hours, i.e. following a dry heat 
treatment validated for the reduction of the endotoxin content of at least 3 log units 
Contaminate the filter with 10 L of a Control Standard Endotoxin solution with a 
concentration of 25 IU/mL 
Cut the filter into 4 pieces and place it into a beaker together with 5 mL of an 0.05% 
aqueous solution of Tween 20 (endotoxin theoretical concentration equal to or near the 
middle of the standard curve, i.e. 0.05 IU/mL). 
Cover the beaker with parafilm and shake it with orbital shaker at room temperature for 
60 minutes at 250 rpm in one direction only. 
Centrifuge the solution for 15 minutes at 1000 g to eliminate the residues of glass fiber; 
recover the supernatant and analyze it with Chromogenic kinetic LAL test Cartridge ( = 
0.005 IU / mL). 
Carry out LAL test also on: 
- a Negative control: 5 mL of a 0.05% aqueous solution of Tween 20; 
- a Positive Control: 5 mL of a 0.05% aqueous solution of Tween 20 contaminated with 10 
l of a Control Standard Endotoxin solution with a theoretical concentration of 25 
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IU/mL and treated with the same procedure of sample in order to obtain a solution 
with a theoretical concentration of endotoxin equal to 0.05 IU / mL. 
Assessment of the absence of irreversible adsorption of bacterial endotoxins by the 
filter  
Depyrogenate filters, scissors and pliers at 220 ° C for 3 hours, i.e. following a dry heat 
treatment validated for the reduction of the endotoxin content of at least 3 log units 
Contaminate the filter with 10 L of a Control Standard Endotoxin solution with a 
concentration of 25 IU/mL 
Let it dry for 30 minutes under a laminar flow hood, with an orientation such as to be 
perpendicular to the direction of air flow. 
After adjusting the flow rate of the air sampler at a value of 2 L/min with the help of a 
calibrated flowmeter, insert the filter into the holder of the air sampler and sample a 
volume of air equal to 100 L for a time of 50 minutes under a laminar flow hood. 
Then, remove the filter from the sampler, cut it into 4 pieces and transfer it into a 25 mL 
beaker. 
Add immediately 5 mL of 0.05% aqueous solution of Tween 20, in order to obtain a 
theoretical concentration of endotoxin equal to 0.05 IU / mL. 
Cover the beaker with parafilm and shake it with orbital shaker at room temperature for 
60 minutes at 250 rpm in one direction only. 
Centrifuge the solution for 15 minutes at 1000g to eliminate the residues of glass fiber; 
recover the supernatant and analyze it with Chromogenin kinetic LAL test Cartridge ( = 
0.005 IU / mL). 
Carry out LAL test also on: 
- a Negative control: a non-contaminated filter, treated in the same way of the 
contaminated one. 
- a Positive Control: 5 mL of a 0.05% aqueous solution of Tween 20 contaminated with 10 
L of a Control Standard Endotoxin solution with a theoretical concentration of 25 
IU/mL and treated with the same procedure of sample in order to obtain a solution with 
a theoretical concentration of endotoxin equal to 0.05 IU / mL. 
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Evaluation of endotoxins holding time by filters 
Contaminate at least five depyrogenated filters with 10 L of a Control Standard 
Endotoxin solution with a theoretical concentration of 25 IU/mL and let them dry for 90 
minutes under a laminar flow hood, with an orientation such as to be perpendicular to 
the direction of air flow. 
Then, transfer four filters each in a sterile Petri dish, seal the latter with parafilm and 
store them in the refrigerator (2÷ 8 °C). 
Cut the not stored filter into 4 pieces and transfer it into a beaker in order to analyze it 
soon (t=0); add 5 mL of 0.05% aqueous solution of Tween 20, in order to obtain a 
theoretical concentration of endotoxin equal to 0.05 IU / mL. 
Cover the beaker with parafilm and shake it with orbital shaker at room temperature for 
60 minutes at 250 rpm in one direction only. 
Centrifuge the solution for 15 minutes at 1000 g to eliminate the residues of glass fiber; 
recover the supernatant and analyze it with Chromogenic kinetic LAL test Cartridge ( = 
0.005 IU / mL). 
Carry out LAL test also on: 
- a Negative control: non-contaminated filter, treated in the same way of the 
contaminated one; 
- a Positive Control: 5 mL of a 0.05% aqueous solution of Tween 20 contaminated with 10 
l of a Control Standard Endotoxin solution with a theoretical concentration of 25 IU/mL 
and treated with the same procedure of sample in order to obtain a solution with a 
theoretical concentration of endotoxin equal to 0.05 IU / mL. 
Analyze the stored filters in the same way after four different times (minimum time 
period: 24 h) and for each test carry out LAL test also on a Negative control, i.e. 5 mL of a 
0.05% aqueous solution of Tween 20. 
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9.2. Revision of the validation method for recovering airborne 
endotoxins 
In this part the changes made on the Section 9.1 after the unsatisfactory tests results, are 
explained. 
The most important change was the employment of Kinetic turbidimetric test as BET; 
therefore, we eliminated all the equipment  used for the chromogenic test and we 
inserted  those we need, i.e. tube glass 8 x 75 mm, test tubes incubator-reader and LAL 
reagent with  0.005 IU/mL.   
Compared to the pre-filled cartridges, the Kinetic turbidimetric test provides the 
preparation of the calibration curve, of the sample spikes and of the LAL reagent solution. 
The calibration curve is prepared diluting the reconstituted solution "mother" of Control 
Standard Endotoxin (CSE BRP), so as to obtain three solutions with concentration 
respectively equal to 0.125  IU/mL, 0.025 IU/mL and 0.005 IU/mL. 
The sample spikes are needed only in the first test (“assessment of  the  filter 
compatibility with test of bacterial endotoxins”) in order to verify the absence of an 
extract interference with BET; the sample spikes shall have an endotoxin concentration of 
0.05 IU/mL, so 100 l of a solution of Control Standard Endotoxin (CSE BRP) with a 
concentration of 0.5 IU / mL shall be add to 0.9 mL of extract. 
The LAL reagent solution is reconsitued following the manufacturer indications. 
Moreover, we change the volume of the exctraction solution in 10 mL of 0.05% aqueous 
solution of Tween 20 and we add a dilution ratio of  1 => 2 for the surnatant; for this 
reason, in order to obtain an endotoxin theoretical concentration of the sample or of the 
Positive control equal to 0.05 IU/mL, the contamination is made with 10 L of a dilution of 
Standard Endotoxin having theoretical concentration 100 IU/mL. 
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9.3. Suitability test of the growth media for Gram-negative bacteria 
The Growth promotion test (GPT) is an important function used in the most important 
Pharmacopoeia to determine the suitability of media used in pharmaceutical tests; the 
purpose of the GPT is to assure the nutritive properties of a medium by challenging it with 
a small number of microorganism. 
For each type of media used the EP specifies the strains to inoculate on the media; for 
VRBGA the test strains are Pseudomonas aeruginosa and Escherichia coli (36). 
The amount of the inoculum is 100 L and the plates shall be incubate at 30-35 °C for 48 
hours. 
Moreover, for surfaces sampling, the medium (VRBGA) was added with 3% Tween 80 i.e. 
a polysorbate considerate by EP as a neutralizing  agent suitable to inactivate quaternary 
ammonium cation disinfectants (QACs) , antimicrobial agents likely present on the 
surfaces. 
In order to demonstrate the neutralizing agent efficiency and the absence of toxicity for 
microorganism we carried out a growth promotion test on the medium challenged using 
disinfectants and on a blank with neutralizer and without bacteria inoculation. 
For this scope: 
- prepare two solutions (10 L) respectively of two different type of QACs as 
indicated by disinfectant supplier and  immerse in each solutions one panel of PVC 
(the same material of the floors) for 15 minutes; then, let the surfaces dry under a 
laminar flow hood for 30 minutes (Fig. 19): 
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Figure 20 - Panels' drying under a laminar flow hood 
- Remaining under a laminar flow hood, open and reverse three a contact plate (ᴓ 
55 mm containing 18 mL of medium), on each surfaces and imprint a moderate 
and continue pressure for about 10 seconds preventing any movement on the 
surface. 
- Contaminate two of the three plates, respectively, with 100 L of Escherichia coli 
and Pseudomonas aeruginosa. The remaining two are the blanks. 
- Incubate all plates upside down at 30  35 ° C, and perform the colony counts 
after 2 days. 
- Contaminate two contact plates not previously applied on disinfected PVC surface, 
respectively, with Escherichia coli and Pseudomonas aeruginosa; incubate all 
upside down at 30  35 ° C, and perform the colony counts after 4 days. 
- Contaminate two Petri plates containing non selective medium Soybean Casein 
Digest Agar (TSA), respectively, with Escherichia coli and Pseudomonas 
aeruginosa; incubate all upside down at 30  35 ° C, and perform the colony 
counts after 2 days. 
  
Laminar 
flow hood 
 
Panels  
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9.4. Environmental monitoring of injectable drugs clean areas 
In this part the materials and the experimental parameters employed in the 
environmental monitoring of injectable drugs clean areas are explained; all the tests are 
conducted in triplicate. 
Materials 
- Vortex mixer 
- Gilson type pipettes 
- LAL depyrogenated materials in borosilicate glass: 18 x 150 mm and 8 x 75 mm 
test tubes, glass pipettes, 25 mL beaker. 
- ATi320 
- PVC panels 
- Klercide -CR unit X and Y unit detergents 
- Cloths soaked with 70% IPA 
- Thermostat 
- Freezer (-80±5° C) 
- Sterile Petri dishes of ᴓ 90 mm in polystyrene  
- LAL Reagent Water (LRW) 
- LAL reagent ( = 0.005 UI/mL) 
- Tween 20 and Tween 80 
- Timer 
- Plates contact type " RODAC " ᴓ 55 mm  
- Control Standard Endotoxin (CSE BRP) 
- Air Sampler  
- Flowmeter 
- Filter Holder 
- Glass Fiber Filter (GFF) GF / 1 ᴓ 37 mm  
- Cellulose pad ᴓ 37 mm  
- Orbital shaker 
- Centrifuge 
- TSA: Soybean casein digest agar 
- VRBGA: Violet red bile glucose agar 
70 
 
 
Dynamic sampling and analysis for searching airborne endotoxins. 
After adjusting  the flow rate of the air sampler at a value of 2 L/min with the help of a 
calibrated flowmeter, insert the filter into the holder of the air sampler and sample a 
volume of air equal to 100 L for a time of 50 minutes; the sampler should be resting on a 
stand, which allows to keep it on a level of 1.5 m above the floor (Fig.20). 
Remove the filter from the sampler, transfer it in a sterile Petri dish and seal the latter 
with parafilm; store it in the freezer (- 80±5 °C) for a maximum of 4 days. 
In order to analyze the sample, rebalance at room temperature the filter inside the plate, 
cut it  into 4 pieces and transfer it to a beaker. 
Then, add immediately 10 mL of an 0.05% aqueous solution of Tween 20. cover the 
beaker with parafilm and shake it with orbital shaker at room temperature for 60 minutes 
at 250 rpm in one direction only. 
Centrifuge the solution for 15 minutes at 1000 g, recover the supernatant and dilute 1 => 
2 with LRW; then, stir it for 1 minute with Vortex at 18 rpm. 
Prepare the calibration curve by diluting the solution "mother" of Control Standard 
Endotoxin (CSE BRP ), so as to obtain three solutions with concentration respectively 
equal to 0.125 IU/mL , 0.025 IU/mL and 0.005 IU/mL. 
Reconstitute the LAL reagent. 
Using incubator-reader perform kinetic turbidimetric LAL test on: 
- the extract solution 
- the three dilution of the standard curve; for each concentration not less than two 
replicates shall be made 
- the Negative Control: a depyrogenated filter subjected to same extraction 
procedure of the analyzed sample 
- at least one Sample spike obtained by adding 100  l of standard endotoxin at a 
concentration of 0.5 IU/mL to 0.9 mL of extract (theoretical concentration of 0.05 
IU/mL). 
For the test to be considered as valid, the Negative control must have endotoxin content 
 QL (0.005 IU/mL) and the measured concentration of Spiked sample must be within 50-
200 per cent of the known added endotoxin concentration (0.05IU/mL), after subtraction 
of any endotoxin detected in the other two channel without added endotoxin. 
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Static sampling and analysis for searching airborne Gram negative bacteria 
On a stand at 1.5 m above the floor Expose to the air for two hours an open plate (ᴓ 90 
mm) containing  30 mL of  VRBGA. 
 
Figure 21 – Settling plates on the stand 
Identify each of the plates with the corresponding abbreviation of the sampling location, 
incubate them upside down at 30  35 ° C and count the colony (cfu) grown after 3 days; 
calculate the C.F.U present after 4 hours of sampling. 
 
Surfaces sampling for and analysis for searching Gram-negative bacteria 
Open and reverse on the floor a contact plate (ᴓ 55 mm), containing 18 mL of VRBGA 
added with 3 % Tween 80; imprint a moderate and continue pressure for about 10 
seconds preventing any movement on the surface sampled. 
After sampling, decontaminate the affected area with a cloth soaked in 70% isopropyl 
alcohol (IPA). 
Identify each of the plates with the corresponding abbreviation of the sampling location, 
incubate them upside down at 30  35 ° C and count the colony (cfu) grown counts after 3 
days.  
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10. Appendices 
Appendix 1 – Volatility of lypopolisaccharide 
For the evaluation of the volatility of LPS we search amphipatic molecules with much 
inferior molecular mass; if these molecules have a low value of vapor pressure, thus we 
can consider the LPS as a nonvolatile compound. 
On the basis of Log P value reported in the database SciFinder, we chose both a more 
hydrophobic and a more hydrophilic molecules than LPS; the latter has a Log P = -4÷-10 
and a Molecular weight 10kDa-20kDa.  
Tryolein (Fig.21): 
- Log P: 23,444 ± 0.279 (a t° = 25 °C) 
- Molecular Weight: 885,43 Da 
- Vapor Pressure: 6,66 x 10-27 Torr (t° = 25 °C) 
 
Figure 22- Tryolein 
D-myo-Inositol (Fig. 22): 
- Log P: -7,954 ± 0.581 (a t° = 25 °C) 
- Molecular Weight: 494,17 Da 
- Vapor Pressure: 0 Torr (t° = 25 °C) 
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Figure 23 - D-myo-Inositol 
 
Appendix 2 – Experimental data of glass fiber filter UV/visible 
spectroscopy.  
The first test of the airborne endotoxins validation assay showed a significant interference 
with Chromogenic Kinetic test and, since we know a 0.05% aqueous solution of Tween 20 
does not create any interference with the test, we decide to verify if the glass fibers of the 
filters  adsorbs at the same wavelength at which the release of the chromophore (p-
nitroanilina) of LAL reagent is measured (450 nm); thus, we perform a spectroscopic test 
in the range of UV/visible wavelength (300-780 nm) on the extract (Fig. 23):  
 
Figure 24 - Extract spectroscopic graphic 
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Appendix 3 – MVD Calculation  
EP defines the MVD as “the maximum allowable dilution of a sample at which the 
endotoxin limit can be determined” (18) and provide the following equation for its 
calculation: 
 
Where: 
* Concentration of test solution can be expressed as: 
- mg/mL if the endotoxin limit is specified by mass (IU/mg), 
- Units/mL if the endotoxin limit is specified by unit of biological activity 
(IU/Unit), 
- mL/mL if the endotoxin limit is specified by volume (IU/mL). 
* λ = “the labelled lysate sensitivity in the gel-clot technique (IU/mL) or the lowest 
concentration used in the standard curve of the turbidimetric or chromogenic 
techniques” (18). 
 
In order to calculate the MVD of extract in the quantification test of airborne endotoxins, 
we considered the OEL proposed by DECOS, i.e. 90 IU/m38h, as the endotoxin limit and 
we applied to it a covering factor of 10. 
Since the volume of sampling is 100 m3 (i.e. 0.1 mL) and the volume of the extraction 
solution is 5 mL for KC technique and 10mL for KT technique, the concentration of the 
extract is respectively  0.02 mL/mL and 0.01 mL/mL. 
Since  is 0.005 IU/mL the MVD is:  
𝑀𝑉𝐷𝐾𝐶  =
90 𝐼𝑈/𝑚𝐿 × 0.02 𝑚𝐿/𝑚𝐿
10 × 0.005 𝐼𝑈/𝑚𝐿
= 36 
𝑀𝑉𝐷𝐾𝑇  =
90 𝐼𝑈/𝑚𝐿 × 0.01 𝑚𝐿/𝑚𝐿
10 ×  0.005 𝐼𝑈/𝑚𝐿
= 18 
Therefore, we can safely dilute 1 => 10 with LRW the KC extract and 1 =>2 with LRW the KT 
extract. 
  
endotoxin limit x concentration of the test solution 

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